A Nature Biotechnology study showed that delivering mRNA encoding antimicrobial peptibodies to the lung, packaged in anti‑inflammatory lipid formulations, eradicated multidrug‑resistant bacterial pneumonia in mouse models. The approach encodes peptide‑based antimicrobials fused to antibody scaffolds (peptibodies) so lungs transiently produce the therapeutic locally after mRNA delivery, boosting potency and reducing systemic exposure. Authors report robust bacterial clearance and reduced resistance emergence in preclinical models, offering a new strategy to address antibiotic‑resistant respiratory infections and illustrating how mRNA therapeutics can be repurposed beyond vaccines.